Transgenomic Eyes COLD-PCR as Key Revenue Driver via Pharma Pacts, Dx Sales and Services | GenomeWeb

Transgenomic said yesterday that it has contracts in place with three undisclosed pharmaceutical companies and is in discussions with "many more" to explore applications for its recently licensed technology for coamplification at lower denaturation temperature, or COLD, PCR.

The company also updated investors on how it expects the COLD-PCR technology to drive future revenues through diagnostic kit sales and testing services, and create new opportunities to work with the pharmaceutical sector to create companion diagnostic assays.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.